Spotlight Growth
No Result
View All Result
Saturday, March 25, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

This Small-Cap Biotech Stands Out From its Peers, Estimates Strong Sales Growth of 41% Next Year

by admin
March 18, 2022
in Bio/Med/Pharma
0
Small-Cap Biotech Stocks to Watch Undervalued Spotlight Growth

Small-Cap Biotech Stocks to Watch Undervalued Spotlight Growth

The small-cap biotech sector is a favorite of growth investors, but the space can be fraught with highly volatile companies prone to wild price swings where profitability is a far-off dream.  Catalyst Pharmaceuticals (NASDAQ: CPRX) represents the rare stock in the space that has a proven track record, a reasonable valuation, profitable operations, and attractive growth prospects.  For investors seeking to add healthcare exposure to their portfolios, CPRX could be worth a look.  The Coral Gables, FL-based Catalyst was founded in 2002 and has a market cap of $780 million.

Catalyst develops and sells therapeutics for patients with rare, chronic neuromuscular and neurological diseases and disorders.  The flagship product is Firdapse, which is a proprietary phosphate treatment for people with Lambert-Eaton Myasthenic Syndrome (LEMS), myasthenia gravis, and Ruzurgi, both on the adult and pediatric sides.  LEMS is a rare neuromuscular disease where the immune system attacks the body’s cells and causes a breakdown in the body’s ability to send signals to nerve and muscle cells.

Firdapse (clinical name Amifampridine) is the only evidence-based FDA-approved LEMS treatment on the market for adult patients.  It is also approved by the European Medicines Agency.  Catalyst also received approval for the product in Canada in 2020 and is currently working to receive approval in Japan.  Firdapse improves the communications of a signal called acetylcholine (Ach) between nerves and muscles.

CPRX Summary; Source: Stock Rover
CPRX Summary; Source: Stock Rover

Turning to fundamentals, Catalyst has solid gross profitability of 85.5% and net profitability of 31.2% coupled with a price-to-earnings ratio (P/E) of 20.7.  These marks compare favorably to the biotech industry averages of 74% gross margin, 5% net margin, and the industry P/E is not available due to the large number of unprofitable companies that inhabit the space.

The analyst community is bullish on CPRX with five firms publishing coverage, all with a Strong Buy rating.  The positive sentiment is most likely due to the company’s robust growth prospects, a bright spot within the industry.  Catalyst is forecast to grow sales by 41% next year and earnings by 77.5%, compared to the industry estimates of -11.7% for sales and -5.7% for earnings for the same period.  On the valuation side, Catalyst has an EV/EBITDA of 12.4 where the industry average is 17.8, suggesting upside potential for CPRX.  A profitable company that is also set up for future growth is somewhat of an anomaly in the small-cap biotech arena, so Catalyst is a positive outlier.

Catalyst Pharmaceuticals has a compelling story as they have the only FDA-approved treatment in their space.  The company has twenty years of track record, a profitable product line, and is in the process of opening up new markets.  The company seems reasonably valued and while it is more volatile than the overall market with a beta of 1.23, it represents an interesting opportunity for investors seeking small-cap biotech stocks to add to their holdings.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: biopharmaceuticalsbiotechbiotech stocksbiotechnologyCatalyst Pharmaceuticalscommon stockCPRXCPRX newsCPRX stockday tradingemerging growthinvestinginvesting newsinvestmentmedicalmicrocap stocksNASDAQnewspharmaceuticalspublic companysalesservicessmall cap biotechsmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to buystocks to watchtechnology stockstradingtreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Is U.S. Government Trying to Ban Crypto Spotlight Growth

Is The U.S. Government Trying to Ban Crypto?

March 23, 2023
Bioadaptives OTC Pink BDPT LOI World Wellness Health and Wellness Spotlight Growth

Bioadaptives (OTC Pink: BDPT) Signs LOI with World Wellness, LLC to Develop New Health and Wellness Products

March 23, 2023
JanOne NASDAQ JAN Sells ARCA Recycling Business Focus on Biopharma Spotlight Growth

JanOne (NASDAQ: JAN) Sells ARCA Recycling Business to VM7, Will Focus on Budding Biopharmaceuticals Business

March 22, 2023
89bio NASDAQ ETNB Phase 2b ENLIVEN Trial Pegozafermin NASH Spotlight Growth

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

March 22, 2023

Recent News

Is U.S. Government Trying to Ban Crypto Spotlight Growth

Is The U.S. Government Trying to Ban Crypto?

March 23, 2023
Bioadaptives OTC Pink BDPT LOI World Wellness Health and Wellness Spotlight Growth

Bioadaptives (OTC Pink: BDPT) Signs LOI with World Wellness, LLC to Develop New Health and Wellness Products

March 23, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested